Moore Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Moore Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-250,000	Closed	-$2.91M	–	621
2025 Q2	$2.91M	Buy	+250,000	New	+$2.27M	0.04%	281
2022 Q4	–	Sell	-145,792	Closed	-$1.04M	–	546
2022 Q3	$1.04M	Buy	145,792 +121,102	+490%	+$1.14M	0.02%	404
2022 Q2	$200K	Sell	24,690 -28,679	-54%	-$252K	0.01%	449
2022 Q1	$741K	Sell	53,369 -103,242	-66%	-$1.62M	0.02%	444
2021 Q4	$4.39M	Buy	156,611 +54,289	+53%	+$1.66M	0.09%	248
2021 Q3	$3.48M	Buy	102,322 +21,312	+26%	+$771K	0.05%	339
2021 Q2	$3.31M	Buy	81,010 +54,401	+204%	+$2.11M	0.05%	369
2021 Q1	$1.07M	Sell	26,609 -80,770	-75%	-$4.37M	0.01%	503
2020 Q4	$6.35M	Buy	+107,379	New	+$5.54M	0.07%	194

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moore Capital Management's ADPT Position: Q3 2025 in Review

Moore Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2025, closing a stake of 250,000 shares — an estimated $2.91M sold.

Moore Capital Management first reported a position in ADPT in Q4 2020 and held it in 9 quarters. The position peaked at $6.35M in Q4 2020. 271 funds tracked by Wall St. Rank hold ADPT as of Q3 2025.

Moore Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2025 after selling out during the quarter.
Moore Capital Management sold 250,000 Adaptive Biotechnologies shares in Q3 2025, an estimated $2.91M.
Moore Capital Management first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 9 quarters.
Moore Capital Management's Adaptive Biotechnologies position peaked at $6.35M in Q4 2020.
271 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2025.

Based on Moore Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.